Search
Vaccines Treatment Options
A collection of 948 research studies where Vaccines is the interventional treatment. These studies are located in the United States. Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
1 - 12 of 948
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants
Active Not Recruiting
Human papillomavirus (HPV) is a common sexually-transmitted virus which causes infections that usually last only a few months, but sometimes can last a long time and cause cancers of the cervix, vagina, vulva, anus or oropharynx over many years among adults. This phase IIA trial studies how well does the nonavalent HPV vaccine (which can prevent nine different types of HPV) work when given in an alternative dosing schedule to heathy young research participants.
Gender:
ALL
Ages:
Between 9 years and 11 years
Trial Updated:
07/11/2025
Locations: Banner University Medical Center - Tucson, Tucson, Arizona +1 locations
Conditions: Human Papillomavirus-Related Carcinoma
Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
Recruiting
Background:
Epstein-Barr virus (EBV) is the primary cause of infectious mononucleosis, commonly known as mono. EBV infects more than 90% of the world s population. Mono can be serious, and it can lead to severe illnesses like cancer and autoimmune diseases. Researchers want to test vaccines that may help prevent EBV and associated diseases.
Objective:
To test two EBV vaccines: EBV gH/gL/gp42-ferritin and EBV gp350-ferritin.
Eligibility:
Healthy EBV-negative or EBV-positive people aged 18 to... Read More
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
07/10/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: EBV, Epstein-Barr Virus Infection, Infectious Mononucleosis, Mono
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
Active Not Recruiting
This is a Phase 1, single-site, comparator-controlled, dosage-escalating study of an intramuscularly administered mRNA-LNP vaccine encoding for DCVC H1 HA in up to 50 adult volunteers aged 18 to 49 years, inclusive. This study is designed to assess the safety and immunogenicity of two doses of DCVC H1 HA mRNA vaccine administered 28 days apart. Eligible participants will be sequentially enrolled into dosage escalation groups (10 mcg, 25 mcg, and 50 mcg). A separate group of 10 participants will... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
07/10/2025
Locations: University of Iowa - Infectious Disease Clinic, Iowa City, Iowa
Conditions: Influenza
A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults
Recruiting
This is a phase 1, multicenter, randomized, double-blind trial of two influenza A/H5 mRNA-based vaccines on healthy adult participants, 18-49 years of age. Stage 1 will serve as the open-label, dose finding stage. The first 10 participants will receive 12.5 mcg of H5 AC-Anhui RNA vaccine (Group 1), and the second 10 participants will receive 25 mcg of H5 AC-Anhui RNA vaccine (Group 2). After Protocol Safety Review Team (PSRT) review of reactogenicity and safety data through Day 8 for both Groups... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
07/10/2025
Locations: Duke Vaccine and Trials Unit, Durham, North Carolina +2 locations
Conditions: Avian Influenza
Text4Vax: Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-25 Season
Completed
This multi-site study assesses the impact of text message reminders on the receipt of COVID-19 and influenza text message reminders takes place primarily in practices from the American Academy of Pediatrics (AAP) Pediatric Research in Office Settings (PROS) network.
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
07/09/2025
Locations: American Academy of Pediatrics, Itasca, Illinois +3 locations
Conditions: Influenza, COVID-19, Vaccination Hesitancy
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
Active Not Recruiting
This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following:
* to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID conditions.
* to understand characteristics of patients who are receiving COVID-19 vaccines.
All patients whose information is kept unidentified in the HealthVerity database are eligible to be included for both aims of this study.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
07/08/2025
Locations: Pfizer, New York, New York
Conditions: SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome
Active Not Recruiting
This phase IIb trial tests whether Tri-Ad5 in combination with N-803 works to prevent colon and other cancers in participants with Lynch syndrome. Each of the three injections in Tri-Ad5 vaccine contain a different substance that is in precancer and cancer cells. Injecting these substances may cause the immune system to develop a defense against cancer that recognizes and destroys any precancer and cancer cells that produce these proteins in the future. N-803 may increase immune responses to oth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Mayo Clinic Hospital in Arizona, Phoenix, Arizona +13 locations
Conditions: Lynch Syndrome, Colorectal Carcinoma, Colorectal Neoplasm
Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study
Active Not Recruiting
This study is a prospective, randomized clinical trial. During this study, pregnant women will be randomly assigned to receive IIV and mRNA COVID-19 vaccine either simultaneously or sequentially (7-14 days apart). All participants will receive an mRNA COVID-19 vaccine at Visit 1 (Day 1).
Solicited local and systemic symptoms of reactogenicity will be assessed on day of visit for Visits 1 and 2 and daily during the 6 days following each visit using either electronic or paper symptoms diaries, de... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Emory University, Atlanta, Georgia +5 locations
Conditions: Birth Outcomes, Safety, Adverse Event Following Immunization
Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Recruiting
This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20-valent pneumococcal vaccine (Prevnar 20, licensed pneumococcal conjugate vaccine) when they are administered with routine pediatric vaccines in infants aged from approximately 2 months (42 to 89 days).
The study duration per... Read More
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
07/07/2025
Locations: Eclipse Clinical Research- Site Number : 8400029, Tucson, Arizona +80 locations
Conditions: Pneumococcal Immunization
ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients
Active Not Recruiting
This study will enroll 6 DLT evaluable subjects (up to 12 patients total) where we will evaluate feasibility and safety of adoptive cellular therapy combined with IDH1/2 inhibitors in patients with recurrent or progressive oligodendroglioma WHO grade 2 and WHO grade 3.
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
07/07/2025
Locations: University of Florida Health Shands Hospital, Gainesville, Florida
Conditions: Recurrent Oligodendroglioma, Progressive Oligodendroglioma
Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma
Active Not Recruiting
This is a pilot study in a small number of children and young adults with relapsed/progressive medulloblastoma (MB) looking at the feasibility and safety of adoptive cell therapy plus PD-1 blockade.
Gender:
ALL
Ages:
Between 4 years and 30 years
Trial Updated:
07/07/2025
Locations: University of Florida Health, Gainesville, Florida
Conditions: Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Active Not Recruiting
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study.
Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).
COVID-19 sub-study:
The purpose of... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/04/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +295 locations
Conditions: Relapsing Multiple Sclerosis
1 - 12 of 948